论文部分内容阅读
2015 ESC大会公布了OPTILINK-HF试验结果,该研究评估了在心力衰竭(简称心衰)患者置人能够检测胸腔积液量是否超过阈值并自动通知临床医师的装置,能否较标准临床评估降低心衰患者的全因死亡率和心血管事件住院率。研究背景:在失代偿性心衰时,肺部液体聚积通常早于心衰症状和体征的出现。由此,德国Michael Bhm教授牵头开展了Opti Link-HF试验,采用装有胸腔积液超标触发自动报警系统(及时通知医师)的埋藏式心脏转复除颤器(ICD)早期监测胸
The ESC Congress 2015 released the results of the OPTILINK-HF trial, which assessed whether devices in patients with congestive heart failure (heart failure) were able to detect whether pleural fluid volume exceeded the threshold and automatically notify the clinician whether they were lower than the standard clinical assessment All-cause mortality and cardiovascular events in HF patients. Background: In decompensated heart failure, fluid accumulation in the lungs is generally earlier than the onset of heart failure symptoms and signs. As a result, Professor Michael Bhm of Germany led the Opti Link-HF trial using an early detection of the chest with an implanted cardioverter defibrillator (ICD) equipped with an automatic triggering system for pleural effusion triggering (notification in time to the physician)